TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$20 Million

Sienna Biopharmaceuticals

Follow-on Offering

Lead Left Bookrunner, February 2019

Sienna Biopharmaceuticals
Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company is advancing multiple product candidates derived from its Topical by DesignTM platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. The lead candidate from this platform, SNA-120, is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA. The Company recently completed the Phase 2b clinical trial targeting pruritus, or itch, associated with psoriasis. While SNA-120 failed to meet its primary endpoint (pruritus reduction), it did show statistical significance for the secondary endpoint (psoriasis severity reduction). As a result, the Company plans to initiate two pivotal Phase 3 trials for psoriasis in 2H:2019. The second Topical by DesignTM product candidate, SNA-125, is a dual JAK3/TrkA inhibitor currently in Phase 1/2 trials for the treatment of atopic dermatitis and psoriasis